Kerin Adelson, MD

• Adam Roshka
• Adriana Matutino Kahn
• Amer Zeidan
• Andrea Silber
• Anees Chagpar
• Anne Chiang
• Benjamin L. Judson
• Bonnie Gould Rothberg
• Cary Gross
• Daniel Boffa
• David Rimm
• Dmitry Kozhevnikov
• Donald Lannin
• Edieal Pinker
• Elizabeth Horn Prsic
• Erin Hofstatter
• Fangyong Li
• Geliang Gan
• Harold Tara
• Henry S. Park
• Heping Zhang
• Jennifer Kapo
• Jensa Morris
• Jeremy I. Schwartz
• Jeremy Kortmansky
• Jill Lacy
• Joseph Ross
• Justin Persico
• Kim Blenman
• Lajos Pusztai
• Malini Harigopal
• Mariya Rozenblit
• Maureen Canavan
• Melissa Rasar Young
• Michael Cecchini
• Michael DiGiovanna
• Michael S. Leapman
• Michal Marczyk
• Neal Fischbach
• Nikolai Podoltsev
• Nitu Kashyap
• Renee Capasso
• Roy S. Herbst
• Sarah Elizabeth Schellhorn
• Scott Huntington
• Shi-Yi Wang
• Stuart Seropian
• Suzanne B. Evans
• Ted Melnick
• Tristen Park
• Wajih Kidwai

Breast

• Systemic Anticancer Therapy at the End of Life—Changes in Usage Pattern in the Immunotherapy EraCanavan ME, Wang X, Ascha MS, Miksad RA, Calip GS, Gross CP, Adelson KB. Systemic Anticancer Therapy at the End of Life—Changes in Usage Pattern in the Immunotherapy Era. JAMA Oncology 2022, 8: 1847-1849. PMID: 36264566, PMCID: PMC9585458, DOI: 10.1001/jamaoncol.2022.4666.
• Self-Reported COVID-19 Infections and Social Mixing Behavior at Oncology MeetingsTalcott W, Chen K, Peters G, Reddy K, Weintraub S, Mougalian S, Adelson K, Evans S. Self-Reported COVID-19 Infections and Social Mixing Behavior at Oncology Meetings. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e340. PMCID: PMC9595452, DOI: 10.1016/j.ijrobp.2022.07.1432.
• Oncology-hospitalist co-management: A model for efficient, high-quality care and education.Morris J, Prsic E, Parker N, Weber U, Gombos E, Kottarathara M, Rothberg B, Adelson K. Oncology-hospitalist co-management: A model for efficient, high-quality care and education. Journal Of Clinical Oncology 2022, 40: 1-1. DOI: 10.1200/jco.2022.40.28_suppl.001.
• Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm DL, Pusztai L. Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC. Clinical Cancer Research 2022, 28: 3720-3728. PMID: 35903931, PMCID: PMC9444984, DOI: 10.1158/1078-0432.ccr-22-0862.
• Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC.Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm D, Pusztai L. Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC. Journal Of Clinical Oncology 2022, 40: 516-516. DOI: 10.1200/jco.2022.40.16_suppl.516.
• Self-Reported COVID-19 Infections and Social Mixing Behavior at Oncology MeetingsTalcott WJ, Chen K, Peters GW, Reddy KK, Weintraub SM, Mougalian SS, Adelson K, Evans SB. Self-Reported COVID-19 Infections and Social Mixing Behavior at Oncology Meetings. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: 30-38. PMID: 35598798, PMCID: PMC9119957, DOI: 10.1016/j.ijrobp.2022.05.002.
• Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancerFoldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. Npj Breast Cancer 2022, 8: 17. PMID: 35115541, PMCID: PMC8814070, DOI: 10.1038/s41523-022-00392-3.
• Implementation of Inpatient Palliative Care Consultation Triggers and Its Impact on Healthcare Use in Patients with Relapsed/Refractory Acute Myeloid LeukemiaXiang J, Prsic E, Adelson K, Prebet T. Implementation of Inpatient Palliative Care Consultation Triggers and Its Impact on Healthcare Use in Patients with Relapsed/Refractory Acute Myeloid Leukemia. Blood 2021, 138: 3018. DOI: 10.1182/blood-2021-149300.
• A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC)Yardley DA, Young RR, Adelson KB, Silber AL, Najera JE, Daniel DB, Peacock N, Finney L, Hoekstra SJ, Shastry M, Hainsworth JD, Burris HA. A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC). Clinical Breast Cancer 2021, 22: 269-278. PMID: 34824002, DOI: 10.1016/j.clbc.2021.10.011.
• Differences by race in systemic oncologic end-of-life (EOL) care among patients with cancer.Adelson K, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Canavan M. Differences by race in systemic oncologic end-of-life (EOL) care among patients with cancer. Journal Of Clinical Oncology 2021, 39: 137-137. DOI: 10.1200/jco.2020.39.28_suppl.137.
• Trends in end-of- life (EOL) systemic oncologic treatment in contemporary clinical practice: Insights from real-world data.Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. Trends in end-of- life (EOL) systemic oncologic treatment in contemporary clinical practice: Insights from real-world data. Journal Of Clinical Oncology 2021, 39: 253-253. DOI: 10.1200/jco.2020.39.28_suppl.253.
• Impact of an automatic palliative care consultation trigger on healthcare use in patients with relapsed/refractory acute myeloid leukemia.Xiang J, Prsic E, Adelson K, Ozyck R, Prebet T. Impact of an automatic palliative care consultation trigger on healthcare use in patients with relapsed/refractory acute myeloid leukemia. Journal Of Clinical Oncology 2021, 39: 224-224. DOI: 10.1200/jco.2020.39.28_suppl.224.
• Impact of a Dedicated Cancer Urgent Care Center on Acute Care UtilizationRothberg B, Canavan ME, Mun S, Sedghi T, Carafeno T, Raucci M, Dest V, Sinanis N, Gross CP, Adelson KB. Impact of a Dedicated Cancer Urgent Care Center on Acute Care Utilization. JCO Oncology Practice 2021, 18: e129-e136. PMID: 34383579, DOI: 10.1200/op.21.00183.
• Telehealth in Oncology: ASCO Standards and Practice RecommendationsZon RT, Kennedy EB, Adelson K, Blau S, Dickson N, Gill D, Laferriere N, Lopez AM, Mulvey TM, Patt D, Pickard TA, Purdom T, Royce TJ, Sumrall AL, Page RD. Telehealth in Oncology: ASCO Standards and Practice Recommendations. JCO Oncology Practice 2021, 17: 546-564. PMID: 34319760, DOI: 10.1200/op.21.00438.
• Oncology Medical Home: ASCO and COA StandardsWoofter K, Kennedy EB, Adelson K, Bowman R, Brodie R, Dickson N, Gerber R, Fields KK, Murtaugh C, Polite B, Paschall M, Skelton M, Zoet D, Cox JV. Oncology Medical Home: ASCO and COA Standards. JCO Oncology Practice 2021, 17: 475-492. PMID: 34255551, DOI: 10.1200/op.21.00167.
• Bundling cancer subtypes in value-based care: A pilot analysis of lymphoma episodes in the Oncology Care Model.Yue A, Chaudhry B, Schleicher S, Huntington S, Lyss A, Connor N, Tran L, Adelson K. Bundling cancer subtypes in value-based care: A pilot analysis of lymphoma episodes in the Oncology Care Model. Journal Of Clinical Oncology 2021, 39: e18850-e18850. DOI: 10.1200/jco.2021.39.15_suppl.e18850.
• Enduring Barriers to Goals-of-Care Discussions Following Oncologist Communication Skills Training (SCI934)Silva E, Coffee J, Bickell N, Adelson K, Schulman-Green D. Enduring Barriers to Goals-of-Care Discussions Following Oncologist Communication Skills Training (SCI934). Journal Of Pain And Symptom Management 2021, 61: 687-688. DOI: 10.1016/j.jpainsymman.2021.01.095.
• Abstract PS11-29: A phase 2 study evaluating orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic triple-negative breast cancer (TNBC)Yardley D, Young R, Adelson K, Silber A, Kommor M, Najera J, Daniel D, Peacock N, Shastry M, Hainsworth J, Burris H. Abstract PS11-29: A phase 2 study evaluating orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic triple-negative breast cancer (TNBC). Cancer Research 2021, 81: ps11-29-ps11-29. DOI: 10.1158/1538-7445.sabcs20-ps11-29.
• Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancerFoldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. Npj Breast Cancer 2021, 7: 9. PMID: 33558513, PMCID: PMC7870853, DOI: 10.1038/s41523-021-00219-7.
• Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapyRozenblit M, Mun S, Soulos P, Adelson K, Pusztai L, Mougalian S. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy. Breast Cancer Research 2021, 23: 14. PMID: 33514405, PMCID: PMC7844919, DOI: 10.1186/s13058-021-01394-y.
• Creating and Validating a Predictive Model for Suitability of Hospital at Home for Patients With Solid-Tumor Malignancies.Chen K, Desai K, Sureshanand S, Adelson K, Schwartz JI, Gross CP, Chaudhry SI. Creating and Validating a Predictive Model for Suitability of Hospital at Home for Patients With Solid-Tumor Malignancies. JCO Oncology Practice 2021, 17: e556-e563. PMID: 33417488, PMCID: PMC8257922, DOI: 10.1200/op.20.00663.
• Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast CancerKunst N, Wang SY, Hood A, Mougalian SS, DiGiovanna MP, Adelson K, Pusztai L. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer. JAMA Network Open 2020, 3: e2027074. PMID: 33226431, PMCID: PMC7684449, DOI: 10.1001/jamanetworkopen.2020.27074.
• The association between clinical trial (CT) participation, pharmaceutical costs, and savings performance in the Oncology Care Model (OCM).Adelson K, Canavan M, Mun S, Gross C, Sinanis N, Davidoff A. The association between clinical trial (CT) participation, pharmaceutical costs, and savings performance in the Oncology Care Model (OCM). Journal Of Clinical Oncology 2020, 38: 2-2. DOI: 10.1200/jco.2020.38.29_suppl.2.
• Conducting Goals-of-Care Discussions Takes Less Time Than Imagined.Pintova S, Leibrandt R, Smith CB, Adelson KB, Gonsky J, Egorova N, Franco R, Bickell NA. Conducting Goals-of-Care Discussions Takes Less Time Than Imagined. JCO Oncology Practice 2020, 16: e1499-e1506. PMID: 32749930, DOI: 10.1200/jop.19.00743.
• Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life.Riaz F, Gan G, Li F, Davidoff AJ, Adelson KB, Presley CJ, Adamson BJ, Shaw P, Parikh RB, Mamtani R, Gross CP. Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life. JCO Oncology Practice 2020, 16: e1355-e1370. PMID: 32678688, PMCID: PMC8189605, DOI: 10.1200/op.20.00010.
• NCCN Policy Summit: Defining, Measuring, and Applying Quality in an Evolving Health Policy Landscape and the Implications for Cancer Care.Bandini LAM, Gallo L, Johnson T, Martin K, Schatz AA, Adelson K, Loy BA, Walters RS, Wong T, Carlson RW. NCCN Policy Summit: Defining, Measuring, and Applying Quality in an Evolving Health Policy Landscape and the Implications for Cancer Care. Journal Of The National Comprehensive Cancer Network 2020, 18: 820-824. PMID: 32634773, DOI: 10.6004/jnccn.2020.7599.
• Patient and Family Caregiver Considerations When Selecting Early Breast Cancer Treatment: Implications for Clinical Pathway DevelopmentSchulman-Green D, Cherlin E, Capasso R, Mougalian SS, Wang S, Gross CP, Bajaj PS, Eakle K, Patel S, Douglas K, Adelson K. Patient and Family Caregiver Considerations When Selecting Early Breast Cancer Treatment: Implications for Clinical Pathway Development. The Patient - Patient-Centered Outcomes Research 2020, 13: 683-697. PMID: 32508006, DOI: 10.1007/s40271-020-00426-7.
• Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non–Small Cell Lung CancerLeapman MS, Presley CJ, Zhu W, Soulos PR, Adelson KB, Miksad RA, Boffa DJ, Gross CP. Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non–Small Cell Lung Cancer. JAMA Network Open 2020, 3: e207205. PMID: 32511721, PMCID: PMC7280954, DOI: 10.1001/jamanetworkopen.2020.7205.
• NSCLC: Integrating the “Yale model shared decision-making solution” into the practice setting.Adelson K, Herbst R, Peterson P, Ingram M, Oliver B, Agrawal T, Davies M, Rudell E. NSCLC: Integrating the “Yale model shared decision-making solution” into the practice setting. Journal Of Clinical Oncology 2020, 38: 7054-7054. DOI: 10.1200/jco.2020.38.15_suppl.7054.
• The impact of clinical trial (CTr) participation on savings performance in the oncology care model (OCM).Adelson K, Canavan M, Mun S, Gross C, Sinanis N, Davidoff A. The impact of clinical trial (CTr) participation on savings performance in the oncology care model (OCM). Journal Of Clinical Oncology 2020, 38: e19367-e19367. DOI: 10.1200/jco.2020.38.15_suppl.e19367.
• The adoption of immune checkpoint inhibitors and patterns of care at the end of life.Riaz F, Gan G, Li F, Davidoff A, Adelson K, Presley C, Adamson B, Shaw P, Parikh R, Mamtani R, Gross C. The adoption of immune checkpoint inhibitors and patterns of care at the end of life. Journal Of Clinical Oncology 2020, 38: 12027-12027. DOI: 10.1200/jco.2020.38.15_suppl.12027.
• Effects of a Communication Intervention Randomized Controlled Trial to Enable Goals-of-Care Discussions.Bickell NA, Back AL, Adelson K, Gonsky JP, Egorova N, Pintova S, Lin JJ, Kozuch P, Bagiella E, Smith CB. Effects of a Communication Intervention Randomized Controlled Trial to Enable Goals-of-Care Discussions. JCO Oncology Practice 2020, 16: e1015-e1028. PMID: 32374710, DOI: 10.1200/op.20.00040.
• Abstract PD1-01: Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC)Pusztai L, Reisenbichler E, Bai Y, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Killelea B, Chagpar A, Frederick C, Burello T, Blenman K, Rimm D, Silber A. Abstract PD1-01: Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC). Cancer Research 2020, 80: pd1-01-pd1-01. DOI: 10.1158/1538-7445.sabcs19-pd1-01.
• Abstract PD10-05: Cost-effectiveness of different neoadjuvant followed by adjuvant treatment combination strategies for women with HER2-positive breast cancerKunst N, Wang S, Hood A, Mougalian S, DiGiovanna M, Adelson K, Pusztai L. Abstract PD10-05: Cost-effectiveness of different neoadjuvant followed by adjuvant treatment combination strategies for women with HER2-positive breast cancer. Cancer Research 2020, 80: pd10-05-pd10-05. DOI: 10.1158/1538-7445.sabcs19-pd10-05.
• Abstract P1-19-12: Patterns of treatment with everolimus and exemestane in hormone receptor positive HER2 negative metastatic breast cancer in the era of targeted therapyRozenblit M, Pusztai L, Adelson K, Mougalian S. Abstract P1-19-12: Patterns of treatment with everolimus and exemestane in hormone receptor positive HER2 negative metastatic breast cancer in the era of targeted therapy. Cancer Research 2020, 80: p1-19-12-p1-19-12. DOI: 10.1158/1538-7445.sabcs19-p1-19-12.
• Timing and location of palliative care consultation in metastatic pancreatic cancer: A retrospective, single-center observational study.Patel T, Miccio J, Srikumar T, Prsic E, Adelson K, Kozhevnikov D, Patel K, Lacy J, Cecchini M. Timing and location of palliative care consultation in metastatic pancreatic cancer: A retrospective, single-center observational study. Journal Of Clinical Oncology 2020, 38: 770-770. DOI: 10.1200/jco.2020.38.4_suppl.770.
• Impact of High-Quality Goals-of-Care Discussions on Oncologist Productivity.Pintova S, Leibrandt R, Smith CB, Adelson KB, Gonsky JP, Egorova N, Franco R, Bickell NA. Impact of High-Quality Goals-of-Care Discussions on Oncologist Productivity. JCO Oncology Practice 2020, 16: e290-e297. PMID: 32048945, DOI: 10.1200/jop.19.00381.
• Effects of rising drug costs on efforts to control overall cost at a large academic cancer center.Adelson K, Canavan M, Supalla S, Sedghi T, Chaudhry B, Sinanis N, Gross C. Effects of rising drug costs on efforts to control overall cost at a large academic cancer center. Journal Of Clinical Oncology 2019, 37: 2-2. DOI: 10.1200/jco.2019.37.27_suppl.2.
• Development of a time to treatment metric across an NCI designated academic health system.Najarian M, Shaw P, Severino K, Hamrick J, Adelson K. Development of a time to treatment metric across an NCI designated academic health system. Journal Of Clinical Oncology 2019, 37: 307-307. DOI: 10.1200/jco.2019.37.27_suppl.307.
• The Smilow Cancer Hospital Oncology Extended Care Clinic: A Facility Dedicated to Managing Oncologic Urgencies and EmergenciesRothberg B, Dest V, Raucci M, Carafeno T, Sinanis N, Strait M, Judson B, Adelson K. The Smilow Cancer Hospital Oncology Extended Care Clinic: A Facility Dedicated to Managing Oncologic Urgencies and Emergencies. Journal Of Emergency Medicine 2019, 57: 424. DOI: 10.1016/j.jemermed.2019.04.007.
• Treatment-Related Complications of Systemic Therapy and RadiotherapyJairam V, Lee V, Park HS, Thomas CR, Melnick ER, Gross CP, Presley CJ, Adelson KB, Yu JB. Treatment-Related Complications of Systemic Therapy and Radiotherapy. JAMA Oncology 2019, 5: 1028-1035. PMID: 30946433, PMCID: PMC6583836, DOI: 10.1001/jamaoncol.2019.0086.
• Impact of an oncology urgent care clinic on emergency department rates.Sedghi T, Canavan M, Gross C, Davidoff A, Gould Rothberg B, Strait M, Sinanis N, Adelson K. Impact of an oncology urgent care clinic on emergency department rates. Journal Of Clinical Oncology 2019, 37: 6615-6615. DOI: 10.1200/jco.2019.37.15_suppl.6615.
• Understanding cancer care coordination: Opening the black box.Canavan M, Sedghi T, Gross C, Lane S, Bogdan J, Adelson K. Understanding cancer care coordination: Opening the black box. Journal Of Clinical Oncology 2019, 37: e18310-e18310. DOI: 10.1200/jco.2019.37.15_suppl.e18310.
• Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer.Leapman M, Presley C, Zhu W, Soulos P, Adelson K, Boffa D, Gross C. Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer. Journal Of Clinical Oncology 2019, 37: 9059-9059. DOI: 10.1200/jco.2019.37.15_suppl.9059.
• The impact of communication style on patient satisfactionTrant AA, Szekely B, Mougalian SS, DiGiovanna MP, Sanft T, Hofstatter E, Silber A, Adelson KB, Chagpar A, Killelea B, Horowitz N, Lannin D, Park T, Corso M, Abraham G, Pollard-Murphy K, Sturrock T, Knill-Selby E, Western A, Servodidio C, Tasoulis MK, Healy B, Hatzis C, Pusztai L. The impact of communication style on patient satisfaction. Breast Cancer Research And Treatment 2019, 176: 349-356. PMID: 31025271, DOI: 10.1007/s10549-019-05232-w.
• P78 Treatment-Related Complications of Chemotherapy and Radiotherapy: An Analysis of the Nationwide Emergency Department SampleJairam V, Lee V, Park H, Thomas C, Melnick E, Gross C, Presley C, Adelson K, Yu J. P78 Treatment-Related Complications of Chemotherapy and Radiotherapy: An Analysis of the Nationwide Emergency Department Sample. International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e51-e52. DOI: 10.1016/s0360-3016(19)30528-0.
• Thirty-Day Readmissions in Patients With Metastatic Cancer: Room for Improvement?Solomon R, Egorova N, Adelson K, Smith CB, Franco R, Bickell NA. Thirty-Day Readmissions in Patients With Metastatic Cancer: Room for Improvement? JCO Oncology Practice 2019, 15: e410-e419. PMID: 30925070, DOI: 10.1200/jop.18.00500.
• Implementing an Electronic End-of-Life Chemotherapy Utilization MeasureKraut J, Mooney K, Sweetenham JW, Page RD, Adelson K, Agarwala V, Fessele KL, Hamrick HJ, Kaganman I, Martineau J, Abernethy AP, Meropol NJ. Implementing an Electronic End-of-Life Chemotherapy Utilization Measure. JCO Oncology Practice 2019, 15: jop.18.00408. PMID: 30883256, DOI: 10.1200/jop.18.00408.
• Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancerRiaz F, Presley CJ, Chiang AC, Longtine JA, Soulos PR, Adelson KB, Herbst RS, Nussbaum NC, Sorg RA, Abernethy AP, Agarwala V, Gross CP. Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer. Journal Of Geriatric Oncology 2019, 10: 669-672. PMID: 30718180, DOI: 10.1016/j.jgo.2019.01.016.
• Finding the Path: Incorporating Patient Preferences into an Interactive Clinical Pathway Platform (S867)Schulman-Green D, Cherlin E, Capasso R, Mougalian S, Wang S, Gross C, Bajaj P, Eakle K, Adelson K, Patel S. Finding the Path: Incorporating Patient Preferences into an Interactive Clinical Pathway Platform (S867). Journal Of Pain And Symptom Management 2019, 57: 517. DOI: 10.1016/j.jpainsymman.2018.12.317.
• Disparities in length of goals of care conversations between oncologists and patients with advanced cancer.Smith C, Pintova S, Adelson K, Gonsky J, Egorova N, Bickell N. Disparities in length of goals of care conversations between oncologists and patients with advanced cancer. Journal Of Clinical Oncology 2018, 36: 19-19. DOI: 10.1200/jco.2018.36.34_suppl.19.
• Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction.Chiang AC, Lake J, Sinanis N, Brandt D, Kanowitz J, Kidwai W, Kortmansky J, LaSala J, Orell J, Sabbath K, Tara H, Engelking C, Shomsky L, Fradkin M, Adelson K, Uscinski K, Vest K, Lyons C, Lemay A, Lopman A, Fuchs CS, Lilenbaum R. Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction. JCO Oncology Practice 2018, 14: e823-e833. PMID: 30537462, DOI: 10.1200/jop.18.00419.
• Simple interventions to decrease use of chemotherapy in patients at the end of life.Chiang A, Adelson K, Kapo J, Severino K, Lilenbaum R. Simple interventions to decrease use of chemotherapy in patients at the end of life. Journal Of Clinical Oncology 2018, 36: 181-181. DOI: 10.1200/jco.2018.36.30_suppl.181.
• Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER databaseChang E, Mougalian SS, Adelson KB, Young MR, Yu JB. Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database. Breast Cancer Research And Treatment 2018, 173: 209-216. PMID: 30242577, DOI: 10.1007/s10549-018-4968-7.
• Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical TrialsO’Connor J, Fessele KL, Steiner J, Seidl-Rathkopf K, Carson KR, Nussbaum NC, Yin ES, Adelson KB, Presley CJ, Chiang AC, Ross JS, Abernethy AP, Gross CP. Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials. JAMA Oncology 2018, 4: e180798-e180798. PMID: 29800974, PMCID: PMC6143052, DOI: 10.1001/jamaoncol.2018.0798.
• Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non–Small Cell Lung Cancer in the Community Oncology SettingPresley CJ, Tang D, Soulos PR, Chiang AC, Longtine JA, Adelson KB, Herbst RS, Zhu W, Nussbaum NC, Sorg RA, Agarwala V, Abernethy AP, Gross CP. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non–Small Cell Lung Cancer in the Community Oncology Setting. JAMA 2018, 320: 469-477. PMID: 30088010, PMCID: PMC6142984, DOI: 10.1001/jama.2018.9824.
• Association between metastatic free interval and recurrent metastatic breast cancer survival: Findings from the Surveillance, Epidemiology and End Results database.Chang E, Mougalian S, Adelson K, Young M, Yu J. Association between metastatic free interval and recurrent metastatic breast cancer survival: Findings from the Surveillance, Epidemiology and End Results database. Journal Of Clinical Oncology 2018, 36: e13069-e13069. DOI: 10.1200/jco.2018.36.15_suppl.e13069.
• Impact of electronic decision support and targeted educational intervention to increase adherence with ASCO Choosing Wisely breast cancer staging guideline.Konuthula D, Canavan M, Huntington S, Strait M, Vega T, Framski K, Adelson K. Impact of electronic decision support and targeted educational intervention to increase adherence with ASCO Choosing Wisely breast cancer staging guideline. Journal Of Clinical Oncology 2018, 36: e18826-e18826. DOI: 10.1200/jco.2018.36.15_suppl.e18826.
• Impact of oncologist outpatient productivity on prevalence of goals of care discussions.Pintova S, Smith C, Adelson K, Gonsky J, Egorova N, Franco R, Bickell N. Impact of oncologist outpatient productivity on prevalence of goals of care discussions. Journal Of Clinical Oncology 2018, 36: 10106-10106. DOI: 10.1200/jco.2018.36.15_suppl.10106.
• Length of time to conduct goals of care visits.Pintova S, Smith C, Adelson K, Gonsky J, Egorova N, Franco R, Bickell N. Length of time to conduct goals of care visits. Journal Of Clinical Oncology 2018, 36: 10107-10107. DOI: 10.1200/jco.2018.36.15_suppl.10107.
• Development of a dashboard for end-of-life care at an academic hospital.Adelson K, Meropol N, Hamrick J, Haydell T, Martineau J, Kraut J, Severino K, Lilenbaum R. Development of a dashboard for end-of-life care at an academic hospital. Journal Of Clinical Oncology 2018, 36: 6590-6590. DOI: 10.1200/jco.2018.36.15_suppl.6590.
• Does training oncologists to have goals of care discussions affect healthcare utilization among patients with advanced cancer?Bickell N, Adelson K, Gonsky J, Lin J, Franco R, Egorova N, Smith C. Does training oncologists to have goals of care discussions affect healthcare utilization among patients with advanced cancer? Journal Of Clinical Oncology 2018, 36: 6595-6595. DOI: 10.1200/jco.2018.36.15_suppl.6595.
• Does training oncologists to have goals of care discussions increase and improve the quality of GoC discussions with advanced cancer patients?Bickell N, Adelson K, Gonsky J, Lin J, Pintova S, Franco R, Egorova N, Smith C. Does training oncologists to have goals of care discussions increase and improve the quality of GoC discussions with advanced cancer patients? Journal Of Clinical Oncology 2018, 36: 6597-6597. DOI: 10.1200/jco.2018.36.15_suppl.6597.
• Prognostic understanding in acute leukemia: Patient-physician differences.Shimer S, Canavan M, Capasso R, Gore S, Tannenbaum S, Babar T, Podoltsev N, Seropian S, Huntington S, Zeidan A, von Keudell G, Prebet T, Adelson K. Prognostic understanding in acute leukemia: Patient-physician differences. Journal Of Clinical Oncology 2018, 36: e22124-e22124. DOI: 10.1200/jco.2018.36.15_suppl.e22124.
• Redefining Quality Measurement in Cancer Care.Nardi EA, McCanney J, Winckworth-Prejsnar K, Schatz AA, Adelson K, Neubauer M, Smith ML, Walters R, Carlson RW. Redefining Quality Measurement in Cancer Care. Journal Of The National Comprehensive Cancer Network 2018, 16: 473-478. PMID: 29752321, DOI: 10.6004/jnccn.2018.7028.
• Monitoring InBaskets With Feedback to Providers Enhances the Timeliness of Patient Care.Trant AA, Strait M, Kaplan R, Dest V, Roshka A, Lyons CA, Vest KA, Steffen T, Chiang A, Adelson KB. Monitoring InBaskets With Feedback to Providers Enhances the Timeliness of Patient Care. JCO Oncology Practice 2018, 14: e310-e315. PMID: 29641273, DOI: 10.1200/jop.17.00103.
• Using a Best Practices Advisory (BPA) Alert Tool to Identify and Enhance Outpatient Palliative Care (OPC) Referrals for Stage 4 Cancer Patients (FR461B)Swidler M, Kapo J, Adelson K, Kashyap N, Trant A. Using a Best Practices Advisory (BPA) Alert Tool to Identify and Enhance Outpatient Palliative Care (OPC) Referrals for Stage 4 Cancer Patients (FR461B). Journal Of Pain And Symptom Management 2018, 55: 624. DOI: 10.1016/j.jpainsymman.2017.12.138.
• Goals of Care Conversations in Advanced Cancer: Patient Perceptions Versus Reality (FR419B)Smith C, Annadurai V, Adelson K, Pintova S, Gonsky J, Egorova N, Bickell N. Goals of Care Conversations in Advanced Cancer: Patient Perceptions Versus Reality (FR419B). Journal Of Pain And Symptom Management 2018, 55: 604-605. DOI: 10.1016/j.jpainsymman.2017.12.101.
• Development of Imminent Mortality Predictor for Advanced Cancer (IMPAC), a Tool to Predict Short-Term Mortality in Hospitalized Patients With Advanced CancerAdelson K, Lee DKK, Velji S, Ma J, Lipka SK, Rimar J, Longley P, Vega T, Perez-Irizarry J, Pinker E, Lilenbaum R. Development of Imminent Mortality Predictor for Advanced Cancer (IMPAC), a Tool to Predict Short-Term Mortality in Hospitalized Patients With Advanced Cancer. JCO Oncology Practice 2017, 14: jop.2017.023200. PMID: 29206553, DOI: 10.1200/jop.2017.023200.
• Early integration of supportive oncology consultation for hospitalized cancer patients.Woodfield K, Adelson K, Horton J, Smith C. Early integration of supportive oncology consultation for hospitalized cancer patients. Journal Of Clinical Oncology 2017, 35: 136-136. DOI: 10.1200/jco.2017.35.31_suppl.136.
• Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast CancerMougalian SS, Epstein LN, Jhaveri AP, Han G, Abu-Khalaf M, Hofstatter EW, DiGiovanna MP, Silber ALM, Adelson K, Pusztai L, Gross CP. Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast Cancer. JCO Clinical Cancer Informatics 2017, 1: 1-10. PMID: 30657377, DOI: 10.1200/cci.17.00015.
• Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision MakingDzimitrowicz H, Mougalian S, Storms S, Hurd S, Chagpar AB, Killelea BK, Horowitz NR, Lannin DR, Harigopal M, Hofstatter E, DiGiovanna MP, Adelson KB, Silber A, Abu-Khalaf M, Chung G, Zaheer W, Abdelghany O, Hatzis C, Pusztai L, Sanft TB. Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making. JCO Oncology Practice 2017, 13: jop.2017.022731. PMID: 29048991, DOI: 10.1200/jop.2017.022731.
• Patient-derived Interstitial Fluids and Predisposition to Aggressive Sporadic Breast Cancer through Collagen Remodeling and Inactivation of p53Kenny TC, Schmidt H, Adelson K, Hoshida Y, Koh AP, Shah N, Mandeli J, Ting J, Germain D. Patient-derived Interstitial Fluids and Predisposition to Aggressive Sporadic Breast Cancer through Collagen Remodeling and Inactivation of p53. Clinical Cancer Research 2017, 23: 5446-5459. PMID: 28630214, PMCID: PMC5600839, DOI: 10.1158/1078-0432.ccr-17-0342.
• Does coaching goals of care discussion skills make a difference?Bickell N, Adelson K, Gonsky J, Pintova S, Levy B, Lin J, Franco R, Egorova N, Smith C. Does coaching goals of care discussion skills make a difference? Journal Of Clinical Oncology 2017, 35: 6586-6586. DOI: 10.1200/jco.2017.35.15_suppl.6586.
• Does oncologist productivity impact goals of care discussions?Pintova S, Smith C, Adelson K, Gonsky J, Egorova N, Franco R, Bickell N. Does oncologist productivity impact goals of care discussions? Journal Of Clinical Oncology 2017, 35: e21675-e21675. DOI: 10.1200/jco.2017.35.15_suppl.e21675.
• Racial disparities in the use of programmed death-1 checkpoint inhibitors.O'Connor J, Seidl-Rathkopf K, Torres A, You P, Nussbaum N, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy A, Gross C. Racial disparities in the use of programmed death-1 checkpoint inhibitors. Journal Of Clinical Oncology 2017, 35: 3068-3068. DOI: 10.1200/jco.2017.35.15_suppl.3068.
• Disparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer.Presley C, Soulos P, Chiang A, Longtine J, Adelson K, Herbst R, Nussbaum N, Sorg R, Abernethy A, Agarwala V, Gross C. Disparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer. Journal Of Clinical Oncology 2017, 35: 6563-6563. DOI: 10.1200/jco.2017.35.15_suppl.6563.
• Adoption of immunotherapy into real-world practice: Insights from the use of checkpoint inhibitors.O'Connor J, Seidl-Rathkopf K, You P, Nussbaum N, Torres A, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy A, Gross C. Adoption of immunotherapy into real-world practice: Insights from the use of checkpoint inhibitors. Journal Of Clinical Oncology 2017, 35: e14583-e14583. DOI: 10.1200/jco.2017.35.15_suppl.e14583.
• The Oncology Care Model: Perspectives From the Centers for Medicare & Medicaid Services and Participating Oncology Practices in Academia and the CommunityKline R, Adelson K, Kirshner JJ, Strawbridge LM, Devita M, Sinanis N, Conway PH, Basch E. The Oncology Care Model: Perspectives From the Centers for Medicare & Medicaid Services and Participating Oncology Practices in Academia and the Community. American Society Of Clinical Oncology Educational Book 2017, 37: 460-466. PMID: 28561660, DOI: 10.1200/edbk_174909.
• Speaking Up: How Patient and Physician Voices Shaped a Trial to Improve Goals-of-Care DiscussionsSolomon R, Smith C, Kallio J, Fenollosa A, Benerofe B, Jones L, Adelson K, Gonsky JP, Messner C, Bickell NA. Speaking Up: How Patient and Physician Voices Shaped a Trial to Improve Goals-of-Care Discussions. The Patient - Patient-Centered Outcomes Research 2017, 10: 489-501. PMID: 28364384, DOI: 10.1007/s40271-017-0226-z.
• Standardized Criteria for Palliative Care Consultation on a Solid Tumor Oncology Service Reduces Downstream Health Care UseAdelson K, Paris J, Horton JR, Hernandez-Tellez L, Ricks D, Morrison RS, Smith CB. Standardized Criteria for Palliative Care Consultation on a Solid Tumor Oncology Service Reduces Downstream Health Care Use. JCO Oncology Practice 2017, 13: jop.2016.016808. PMID: 28306372, DOI: 10.1200/jop.2016.016808.
• An EPIC electronic decision support tool to identify percentage of patients with stage IV thoracic or gastrointestinal malignancy who would benefit from concurrent palliative care but do not currently receive it.Adelson K, Trant A, Framski K, Swidler M, Kashyap N. An EPIC electronic decision support tool to identify percentage of patients with stage IV thoracic or gastrointestinal malignancy who would benefit from concurrent palliative care but do not currently receive it. Journal Of Clinical Oncology 2017, 35: 133-133. DOI: 10.1200/jco.2017.35.8_suppl.133.
• Development of a complex patient identification process for the CMS’ Oncology Care Model.Sinanis N, Abdelghany O, Strait M, Lyons C, Adelson K. Development of a complex patient identification process for the CMS’ Oncology Care Model. Journal Of Clinical Oncology 2017, 35: 32-32. DOI: 10.1200/jco.2017.35.8_suppl.32.
• Should Cancer Centers start their own specialty pharmacy? Quality and economic data from the oral chemotherapy program at Smilow Cancer Hospital and Yale New Haven Health System.Adelson K, Stutsky M, Fradkin M, Harrison M, Abdelghany O, Morrow B, Smith M, Havriliak R, Kregling S, Lyons C, Chiang A, Cohen H. Should Cancer Centers start their own specialty pharmacy? Quality and economic data from the oral chemotherapy program at Smilow Cancer Hospital and Yale New Haven Health System. Journal Of Clinical Oncology 2017, 35: 108-108. DOI: 10.1200/jco.2017.35.8_suppl.108.
• Monitoring inbaskets with feedback to providers enhances the timeliness of patient care.Adelson K, Trant A, Strait M, Kaplan R, Dest V, Roshka A, Lyons C, Vest K, Steffen T, Lilenbaum R. Monitoring inbaskets with feedback to providers enhances the timeliness of patient care. Journal Of Clinical Oncology 2017, 35: 132-132. DOI: 10.1200/jco.2017.35.8_suppl.132.
• The Oncology Care Model: Perspectives From the Centers for Medicare & Medicaid Services and Participating Oncology Practices in Academia and the CommunityKline R, Adelson K, Kirshner J, Strawbridge L, Devita M, Sinanis N, Conway P, Basch E. The Oncology Care Model: Perspectives From the Centers for Medicare & Medicaid Services and Participating Oncology Practices in Academia and the Community. American Society Of Clinical Oncology Educational Book 2017, 37: 460-466. DOI: 10.14694/edbk_174909.
• Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trialAdelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona-Calero M, Ma CX, Hershman D, Baar J, Klein P, Cigler T, Budd GT, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D. Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial. Npj Breast Cancer 2016, 2: 16037. PMID: 28721390, PMCID: PMC5515340, DOI: 10.1038/npjbcancer.2016.37.
• Preparing for Value-Based Payment: A Stepwise Approach for Cancer CentersAdelson KB, Velji S, Patel K, Chaudhry B, Lyons C, Lilenbaum R. Preparing for Value-Based Payment: A Stepwise Approach for Cancer Centers. JCO Oncology Practice 2016, 12: e924-e932. PMID: 27858564, DOI: 10.1200/jop.2016.014605.
• Electronic Intervention to Improve Structured Cancer Stage Data CaptureCecchini M, Framski K, Lazette P, Vega T, Strait M, Adelson K. Electronic Intervention to Improve Structured Cancer Stage Data Capture. JCO Oncology Practice 2016, 12: e949-e956. PMID: 27650837, DOI: 10.1200/jop.2016.013540.
• Testing Violations of the Exponential Assumption in Cancer Clinical Trials with Survival EndpointsHan G, Schell MJ, Zhang H, Zelterman D, Pusztai L, Adelson K, Hatzis C. Testing Violations of the Exponential Assumption in Cancer Clinical Trials with Survival Endpoints. Biometrics 2016, 73: 687-695. PMID: 27669414, PMCID: PMC6093291, DOI: 10.1111/biom.12590.
• Associations Between End-of-Life Cancer Care Patterns and Medicare Expenditures.Wang SY, Hall J, Pollack CE, Adelson K, Davidoff AJ, Long JB, Gross CP. Associations Between End-of-Life Cancer Care Patterns and Medicare Expenditures. Journal Of The National Comprehensive Cancer Network 2016, 14: 1001-8. PMID: 27496116, PMCID: PMC5577560, DOI: 10.6004/jnccn.2016.0107.
• Onset of side effects and adherence to endocrine therapy in the Breast Cancer Endocrine Therapy Adherence (BETA) pilot study.Epstein L, Jhaveri A, Han G, Abu-Khalaf M, Hofstatter E, Sanft T, DiGiovanna M, Silber A, Adelson K, Chung G, Gross C, Pusztai L, Mougalian S. Onset of side effects and adherence to endocrine therapy in the Breast Cancer Endocrine Therapy Adherence (BETA) pilot study. Journal Of Clinical Oncology 2016, 34: e18136-e18136. DOI: 10.1200/jco.2016.34.15_suppl.e18136.
• A prospective study to assess the effect of a discharge intervention on readmission rates in patients with a low Rothman Index score admitted to the inpatient oncology unit.Sanft T, Famakinwa O, Velji S, Chu T, Yao X, Larkin B, Raucci M, Longley P, Kapo J, Adelson K, Lilenbaum R. A prospective study to assess the effect of a discharge intervention on readmission rates in patients with a low Rothman Index score admitted to the inpatient oncology unit. Journal Of Clinical Oncology 2016, 34: e18198-e18198. DOI: 10.1200/jco.2016.34.15_suppl.e18198.
• Contemporary management of advanced non-small cell lung cancer (aNSCLC) in a large, real-world cohort.Presley C, Harrington E, Gippetti J, Agarwala V, Bowser B, Adelson K, Herbst R, Abernethy A, Gross C. Contemporary management of advanced non-small cell lung cancer (aNSCLC) in a large, real-world cohort. Journal Of Clinical Oncology 2016, 34: e20621-e20621. DOI: 10.1200/jco.2016.34.15_suppl.e20621.
• Using patients’ and oncologists’ voices to shape a communication skills trial.Bickell N, Schulman-Green D, Adelson K, Lin J, Franco R, Solomon R, Smith C. Using patients’ and oncologists’ voices to shape a communication skills trial. Journal Of Clinical Oncology 2016, 34: e18161-e18161. DOI: 10.1200/jco.2016.34.15_suppl.e18161.
• Lactation opposes pappalysin‐1‐driven pregnancy‐associated breast cancerTakabatake Y, Oxvig C, Nagi C, Adelson K, Jaffer S, Schmidt H, Keely PJ, Eliceiri KW, Mandeli J, Germain D. Lactation opposes pappalysin‐1‐driven pregnancy‐associated breast cancer. EMBO Molecular Medicine 2016, 8: 388-406. PMID: 26951623, PMCID: PMC4818749, DOI: 10.15252/emmm.201606273.
• Understanding total cost of cancer care to determine strategic interventions to improve value.Adelson K, Velji S, Patel K, Chaudhry B, Grizzle S, Lyons C, Lilenbaum R. Understanding total cost of cancer care to determine strategic interventions to improve value. Journal Of Clinical Oncology 2016, 34: 4-4. DOI: 10.1200/jco.2016.34.7_suppl.4.
• An electronic intervention to improve structured cancer stage data capture.Adelson K, Framski K, Lazette P, Vega T, Lilenbaum R. An electronic intervention to improve structured cancer stage data capture. Journal Of Clinical Oncology 2016, 34: 151-151. DOI: 10.1200/jco.2016.34.7_suppl.151.
• Multidisciplinary process improvement to optimize oral chemotherapy safety.Amport S, Adelson K, Fradkin M, Havriliak R, Harrison M, Abdelghany O, Kregling S, Wright J, Morrow B, Sterling R, Smith M, Esposito F, Stutsky M, Miller L, Lilenbaum R, Lyons C, Chiang A, Cohen H. Multidisciplinary process improvement to optimize oral chemotherapy safety. Journal Of Clinical Oncology 2016, 34: 134-134. DOI: 10.1200/jco.2016.34.7_suppl.134.
• Ambulatory redesign: Strategies for quality improvement in patient care.Sinanis N, Lyons C, Smith N, McGlennon M, Parker T, Truini C, Major-Campos M, Lacy J, Michaels K, Dest V, Lisitano R, Adelson K, Lilenbaum R. Ambulatory redesign: Strategies for quality improvement in patient care. Journal Of Clinical Oncology 2016, 34: 85-85. DOI: 10.1200/jco.2016.34.7_suppl.85.
• Abstract P5-11-03: Development of an interactive text messaging tool to improve adherence with adjuvant endocrine therapy: Breast cancer endocrine therapy adherence (BETA) pilot studyEpstein L, Jhaveri A, Han G, Abu-Khalaf M, Hofstatter E, Sanft T, DiGiovanna M, Silber A, Adelson K, Chung G, Pusztai L, Gross C, Mougalian S. Abstract P5-11-03: Development of an interactive text messaging tool to improve adherence with adjuvant endocrine therapy: Breast cancer endocrine therapy adherence (BETA) pilot study. Cancer Research 2016, 76: p5-11-03-p5-11-03. DOI: 10.1158/1538-7445.sabcs15-p5-11-03.
• Trends in end-of-life cancer care in the Medicare programWang SY, Hall J, Pollack CE, Adelson K, Bradley EH, Long JB, Gross CP. Trends in end-of-life cancer care in the Medicare program. Journal Of Geriatric Oncology 2016, 7: 116-125. PMID: 26783015, PMCID: PMC5577563, DOI: 10.1016/j.jgo.2015.11.007.
• Chemotherapy Use, Performance Status, and Quality of Life at the End of LifePrigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, Garrido MM, Reid MC, Berlin DA, Adelson KB, Neugut AI, Maciejewski PK. Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. JAMA Oncology 2015, 1: 778-784. PMID: 26203912, PMCID: PMC4828728, DOI: 10.1001/jamaoncol.2015.2378.
• Trends and regional variation of end-of-life cancer care in the Medicare program.Wang S, Hall J, Long J, Pollack C, Bradley E, Adelson K, Gross C. Trends and regional variation of end-of-life cancer care in the Medicare program. Journal Of Clinical Oncology 2015, 33: 9526-9526. DOI: 10.1200/jco.2015.33.15_suppl.9526.
• Outcomes of adjuvant ACT vs. TC chemotherapy in older women with breast cancer.Mougalian S, Long J, Hall J, Adelson K, Abu-Khalaf M, Pusztai L, Gross C. Outcomes of adjuvant ACT vs. TC chemotherapy in older women with breast cancer. Journal Of Clinical Oncology 2015, 33: 1009-1009. DOI: 10.1200/jco.2015.33.15_suppl.1009.
• Abstract P1-12-08: Bortezomib enhances the efficacy of fulvestrant by promoting the aggregation of the ER in the cytoplasmGermain D, Adelson K, Raptis G, Waxman S. Abstract P1-12-08: Bortezomib enhances the efficacy of fulvestrant by promoting the aggregation of the ER in the cytoplasm. 2015, p1-12-08-p1-12-08. DOI: 10.1158/1538-7445.sabcs14-p1-12-08.
• Abstract S6-03: Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: A New York cancer consortium trialAdelson K, Ramaswamy B, Sparano J, Christos P, Wright J, Raptis G, Villalona M, Ma C, Hershman D, Baar J, Klein P, Cigler T, Budd G, Novik Y, Tan A, Tannenbaum S, Goel A, Levine E, Shapiro C, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D. Abstract S6-03: Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: A New York cancer consortium trial. 2015, s6-03-s6-03. DOI: 10.1158/1538-7445.sabcs14-s6-03.
• Development of Smilow's EPIC ambulatory dashboard and the impact on bar code scanning compliance at care centers.Amport S, Shomsky L, Lyons C, Sterling R, Smith M, Beaulieu N, Corjulo D, Adelson K, Chiang A. Development of Smilow's EPIC ambulatory dashboard and the impact on bar code scanning compliance at care centers. Journal Of Clinical Oncology 2014, 32: 166-166. DOI: 10.1200/jco.2014.32.30_suppl.166.
• Characterization of aggressive interventions within 30 days of death in lung cancer patients at Smilow Cancer Hospital (SCH).Zhang B, Adelson K, Velji S, Rimar J, Longley P, Keane B, Chiang A, Lilenbaum R. Characterization of aggressive interventions within 30 days of death in lung cancer patients at Smilow Cancer Hospital (SCH). Journal Of Clinical Oncology 2014, 32: 20-20. DOI: 10.1200/jco.2014.32.30_suppl.20.
• Emergency department (ED) utilization and hospital admission rates among oncology patients at a large academic center and the need for improved urgent care access.Adelson K, Dest V, Velji S, Lisitano R, Lilenbaum R. Emergency department (ED) utilization and hospital admission rates among oncology patients at a large academic center and the need for improved urgent care access. Journal Of Clinical Oncology 2014, 32: 19-19. DOI: 10.1200/jco.2014.32.30_suppl.19.
• Standardized criteria for required palliative care consultation on the solid tumor oncology service.Adelson K, Paris J, Smith C, Horton J, Morrison R. Standardized criteria for required palliative care consultation on the solid tumor oncology service. Journal Of Clinical Oncology 2014, 32: 6623-6623. DOI: 10.1200/jco.2014.32.15_suppl.6623.
• Development of a new oncology quality metric: The rate of evidence-based adherence.Adelson K, Holcombe R. Development of a new oncology quality metric: The rate of evidence-based adherence. Journal Of Clinical Oncology 2014, 32: 6624-6624. DOI: 10.1200/jco.2014.32.15_suppl.6624.
• Comparison of weight loss among early-stage breast cancer patients post chemotherapy: Nutrition education in combination with weight loss acupuncture versus nutrition education alone.Fukui J, Rothwell A, Danesh H, Adelson K, Morris G, Irie H, Port E, Weltz C, Schmidt H, Montgomery G, Mandeli J, Tiersten A. Comparison of weight loss among early-stage breast cancer patients post chemotherapy: Nutrition education in combination with weight loss acupuncture versus nutrition education alone. Journal Of Clinical Oncology 2014, 32: tps652-tps652. DOI: 10.1200/jco.2014.32.15_suppl.tps652.
• Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2-positive breast cancer.Kalinsky K, Chi D, Lee S, Adelson K, Crew K, Chuang E, Makower D, Hershman D, Califano A, Silva J, Maurer M. Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2-positive breast cancer. Journal Of Clinical Oncology 2014, 32: tps666-tps666. DOI: 10.1200/jco.2014.32.15_suppl.tps666.
• Standardized Criteria for Integrated Palliative Care Consultation on the Solid Tumor Oncology Service (S752)Paris J, Smith C, Horton J, Adelson K, Morrison R. Standardized Criteria for Integrated Palliative Care Consultation on the Solid Tumor Oncology Service (S752). Journal Of Pain And Symptom Management 2014, 47: 497-498. DOI: 10.1016/j.jpainsymman.2013.12.170.
• Implementation of Electronic Chemotherapy Ordering: An Opportunity to Improve Evidence-Based Oncology CareAdelson KB, Qiu YC, Evangelista M, Spencer-Cisek P, Whipple C, Holcombe RF. Implementation of Electronic Chemotherapy Ordering: An Opportunity to Improve Evidence-Based Oncology Care. JCO Oncology Practice 2013, 10: e113-e119. PMID: 24371301, DOI: 10.1200/jop.2013.001184.
• Abstract OT2-6-05: Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancerKalinsky K, Chi D, Lee S, Adelson K, Andreopoulou E, Crew K, Vahdat L, Sparano J, Hershman D, Califano A, Silva J, Maurer M. Abstract OT2-6-05: Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer. Cancer Research 2013, 73: ot2-6-05-ot2-6-05. DOI: 10.1158/0008-5472.sabcs13-ot2-6-05.
• Standardized criteria for required palliative care consultation on the solid tumor oncology service.Adelson K, Paris J, Smith C, Horton J, Morrison R. Standardized criteria for required palliative care consultation on the solid tumor oncology service. Journal Of Clinical Oncology 2013, 31: 37-37. DOI: 10.1200/jco.2013.31.31_suppl.37.
• Development of a new oncology quality metric: The rate of evidence-based adherence.Adelson K, Holcombe R. Development of a new oncology quality metric: The rate of evidence-based adherence. Journal Of Clinical Oncology 2013, 31: 84-84. DOI: 10.1200/jco.2013.31.31_suppl.84.
• Implementation of electronic chemotherapy ordering: An opportunity to improve evidence-based oncology care.Adelson K, Holcombe R, Lutkowski K, Peralta-Hernandez D, McLean M, Evans-Smith A, Wynter D, Spencer-Cisek P. Implementation of electronic chemotherapy ordering: An opportunity to improve evidence-based oncology care. Journal Of Clinical Oncology 2012, 30: 323-323. DOI: 10.1200/jco.2012.30.34_suppl.323.
• Practice patterns in the use of adjuvant therapy for post-menopausal early-stage breast cancer in the pre- and post-Onco type DX era.Latif A, Small A, Moshier E, Adelson K, Raptis G, Godbold J, Oh W, Galsky M. Practice patterns in the use of adjuvant therapy for post-menopausal early-stage breast cancer in the pre- and post-Onco type DX era. Journal Of Clinical Oncology 2012, 30: e21032-e21032. DOI: 10.1200/jco.2012.30.15_suppl.e21032.
• OT3-01-01: Randomized Phase II Study of Fulvestrant Versus Fulvestrant Plus Bortezomib in Postmenopausal Women with Estrogen Receptor (ER) Positive, Aromatase-Inhibitor (AI) Resistant Metastatic Breast Cancer (MBC): New York Cancer Consortium Trial P8457.Adelson K, Raptis G, Sparano J, Germain D. OT3-01-01: Randomized Phase II Study of Fulvestrant Versus Fulvestrant Plus Bortezomib in Postmenopausal Women with Estrogen Receptor (ER) Positive, Aromatase-Inhibitor (AI) Resistant Metastatic Breast Cancer (MBC): New York Cancer Consortium Trial P8457. Cancer Research 2011, 71: ot3-01-01-ot3-01-01. DOI: 10.1158/0008-5472.sabcs11-ot3-01-01.
• OT3-01-03: Pre-Surgical Evaluation of the AKT Inhibitor MK-2206 in Patients with Operable Invasive Breast Cancer: New York Cancer Consortium Trial P8740.Kalinsky K, Sparano J, Kim M, Crew K, Maurer M, Taback B, Feldman S, Hibshoosh H, Wiechmann L, Adelson K, Hershman D. OT3-01-03: Pre-Surgical Evaluation of the AKT Inhibitor MK-2206 in Patients with Operable Invasive Breast Cancer: New York Cancer Consortium Trial P8740. Cancer Research 2011, 71: ot3-01-03-ot3-01-03. DOI: 10.1158/0008-5472.sabcs11-ot3-01-03.
• Hormonal Modulation in the Treatment of Breast CancerAdelson K, Germain D, Raptis G, Biran N. Hormonal Modulation in the Treatment of Breast Cancer. Endocrinology And Metabolism Clinics Of North America 2011, 40: 519-532. PMID: 21889718, DOI: 10.1016/j.ecl.2011.05.011.
• Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer.Kalinsky K, Sparano J, Kim M, Crew K, Maurer M, Taback B, Feldman S, Hibshoosh H, Wiechmann L, Adelson K, Hershman D. Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer. Journal Of Clinical Oncology 2011, 29: tps147-tps147. DOI: 10.1200/jco.2011.29.15_suppl.tps147.
• Abstract P4-02-06: Beyond CYP2D6 Genotyping: Personalized Dosing of Tamoxifen (Tam) Based on Low Serum Endoxifen LevelsBarginear M, Jaremko M, Yu C, Peter I, Kasai Y, Kemeny M, Adelson K, Desnick R, Raptis G. Abstract P4-02-06: Beyond CYP2D6 Genotyping: Personalized Dosing of Tamoxifen (Tam) Based on Low Serum Endoxifen Levels. Cancer Research 2010, 70: p4-02-06-p4-02-06. DOI: 10.1158/0008-5472.sabcs10-p4-02-06.
• Personalized dosing of tamoxifen (Tam) based on polymorphisms of CYP2D6 (2D6) and/or low serum endoxyfen levels.Barginear M, Yu C, Raptis G, Jaremko M, Adelson K, Bulone L, Zuo Q, Peter I, Kemeny M, Desnick R. Personalized dosing of tamoxifen (Tam) based on polymorphisms of CYP2D6 (2D6) and/or low serum endoxyfen levels. Journal Of Clinical Oncology 2010, 28: e13507-e13507. DOI: 10.1200/jco.2010.28.15_suppl.e13507.
• Correlation of Oncotype DX Recurrence Score with Cyclin D1 and ErbB2.Misra D, Adelson K, Halpern M, Jaffer S, Nagi C, Bleiweiss I, Mandeli J, Raptis G, Germain D. Correlation of Oncotype DX Recurrence Score with Cyclin D1 and ErbB2. Cancer Research 2009, 69: 3035-3035. DOI: 10.1158/0008-5472.sabcs-09-3035.
• Wound Fluid Induces Cancer Cell Growth: A Mechanism for Recurrence?Adelson K, Bahadur U, Halpern M, Hauptman E, Barginear M, Bleiweiss I, Ting J, Weltz C, Coomer C, Raptis G, Germain D. Wound Fluid Induces Cancer Cell Growth: A Mechanism for Recurrence? Cancer Research 2009, 69: 3146-3146. DOI: 10.1158/0008-5472.sabcs-09-3146.
• Bortezomib Enhances the Efficacy of Fulvestrant by Promoting the Aggregation of the Estrogen Receptor in the Cytoplasm.Germain D, Bahadur U, Halpern M, Adelson K, Raptis G, Waxman S, Ishii Y. Bortezomib Enhances the Efficacy of Fulvestrant by Promoting the Aggregation of the Estrogen Receptor in the Cytoplasm. Cancer Research 2009, 69: 5142-5142. DOI: 10.1158/0008-5472.sabcs-09-5142.
• Small Bowel TumorsArber N, Adelson K, Sagiv E, Neugut A, Gralnek I, Eliakim R, Bronstein Y, Dubrow R, Nachmany I, Klausner J, Peeters P, Van Cutsem E, Dicato M. Small Bowel Tumors. 2008, 189-226. DOI: 10.1002/9781444300147.ch8.
• Treatment of hot flushes in breast and prostate cancerAdelson KB, Loprinzi CL, Hershman DL. Treatment of hot flushes in breast and prostate cancer. Expert Opinion On Pharmacotherapy 2005, 6: 1095-1106. PMID: 15957964, DOI: 10.1517/14656566.6.7.1095.
• The theoretical basis of transcriptional therapy of cancer: can it be put into practice?Melnick AM, Adelson K, Licht JD. The theoretical basis of transcriptional therapy of cancer: can it be put into practice? Journal Of Clinical Oncology 2005, 23: 3957-70. PMID: 15867201, DOI: 10.1200/jco.2005.14.498.